iCAD, Inc. (NASDAQ: ICAD) Stock Competitors & Peer Comparison
See ICAD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ICAD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ICAD | $3.87 | +3.75% | 106.3M | -20.37 | -$0.19 | N/A |
| ABT | $108.33 | -0.42% | 187.4B | 20.79 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $94.17 | +1.15% | 120.5B | 17.03 | $5.53 | +3.02% |
| SYK | $303.13 | -1.58% | 116.2B | 22.64 | $13.39 | +1.14% |
| BSX | $47.80 | +1.81% | 71.1B | 15.42 | $3.10 | N/A |
| EW | $89.90 | +0.13% | 51.8B | 33.29 | $2.70 | N/A |
| DXCM | $87.90 | -2.02% | 33.2B | 34.47 | $2.55 | N/A |
| GEHC | $68.86 | -1.23% | 31.1B | 15.10 | $4.56 | +0.20% |
| PHG | $25.89 | -0.61% | 25.3B | 14.79 | $1.75 | +3.82% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
ICAD vs ABT Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ABT has a market cap of 187.4B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while ABT trades at $108.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ABT's P/E ratio is 20.79. In terms of profitability, ICAD's ROE is -0.18%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ICAD is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
ICAD vs BSX-PA Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ICAD's ROE is -0.18%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ICAD is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
ICAD vs MDT Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, MDT has a market cap of 120.5B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while MDT trades at $94.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas MDT's P/E ratio is 17.03. In terms of profitability, ICAD's ROE is -0.18%, compared to MDT's ROE of +0.11%. Regarding short-term risk, ICAD is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
ICAD vs SYK Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SYK has a market cap of 116.2B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while SYK trades at $303.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SYK's P/E ratio is 22.64. In terms of profitability, ICAD's ROE is -0.18%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ICAD is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
ICAD vs BSX Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BSX has a market cap of 71.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while BSX trades at $47.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BSX's P/E ratio is 15.42. In terms of profitability, ICAD's ROE is -0.18%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ICAD is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ICAD vs EW Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, EW has a market cap of 51.8B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while EW trades at $89.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas EW's P/E ratio is 33.29. In terms of profitability, ICAD's ROE is -0.18%, compared to EW's ROE of +0.10%. Regarding short-term risk, ICAD is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ICAD vs DXCM Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, DXCM has a market cap of 33.2B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while DXCM trades at $87.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas DXCM's P/E ratio is 34.47. In terms of profitability, ICAD's ROE is -0.18%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ICAD is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
ICAD vs GEHC Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, GEHC has a market cap of 31.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while GEHC trades at $68.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas GEHC's P/E ratio is 15.10. In terms of profitability, ICAD's ROE is -0.18%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ICAD is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ICAD vs PHG Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PHG has a market cap of 25.3B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while PHG trades at $25.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PHG's P/E ratio is 14.79. In terms of profitability, ICAD's ROE is -0.18%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ICAD is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
ICAD vs ZBH Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ZBH has a market cap of 19B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while ZBH trades at $98.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ZBH's P/E ratio is 11.56. In terms of profitability, ICAD's ROE is -0.18%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ICAD is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ICAD vs ABMD Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ICAD's ROE is -0.18%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ICAD is less volatile compared to ABMD. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
ICAD vs PEN Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while PEN trades at $322.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PEN's P/E ratio is 84.16. In terms of profitability, ICAD's ROE is -0.18%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ICAD is less volatile compared to PEN. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ICAD vs SWAV Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ICAD's ROE is -0.18%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ICAD is less volatile compared to SWAV. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
ICAD vs SNN Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while SNN trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SNN's P/E ratio is 13.58. In terms of profitability, ICAD's ROE is -0.18%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ICAD is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ICAD vs ALGN Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while ALGN trades at $158.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ALGN's P/E ratio is 14.46. In terms of profitability, ICAD's ROE is -0.18%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, ICAD is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
ICAD vs GMED Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while GMED trades at $78.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas GMED's P/E ratio is 17.63. In terms of profitability, ICAD's ROE is -0.18%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ICAD is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
ICAD vs GKOS Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, GKOS has a market cap of 10.5B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while GKOS trades at $177.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas GKOS's P/E ratio is -206.37. In terms of profitability, ICAD's ROE is -0.18%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ICAD is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check GKOS's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ICAD vs BIO-B Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while BIO-B trades at $381.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BIO-B's P/E ratio is -67.15. In terms of profitability, ICAD's ROE is -0.18%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ICAD is less volatile compared to BIO-B. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ICAD vs BIO Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while BIO trades at $386.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BIO's P/E ratio is 41.65. In terms of profitability, ICAD's ROE is -0.18%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ICAD is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
ICAD vs PODD Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PODD has a market cap of 10.2B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while PODD trades at $147.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PODD's P/E ratio is 25.12. In terms of profitability, ICAD's ROE is -0.18%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ICAD is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
ICAD vs MASI Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas MASI's P/E ratio is 44.43. In terms of profitability, ICAD's ROE is -0.18%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ICAD is similarly volatile compared to MASI. This indicates similar risk in terms of short-term price fluctuations for ICAD.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
ICAD vs BRKR Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BRKR has a market cap of 8.9B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while BRKR trades at $58.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BRKR's P/E ratio is 29.40. In terms of profitability, ICAD's ROE is -0.18%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ICAD is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
ICAD vs BRKRP Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BRKRP has a market cap of 8.6B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while BRKRP trades at $431.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BRKRP's P/E ratio is 234.13. In terms of profitability, ICAD's ROE is -0.18%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, ICAD is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check BRKRP's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ICAD vs NARI Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NARI's P/E ratio is -59.24. In terms of profitability, ICAD's ROE is -0.18%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ICAD is less volatile compared to NARI. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check NARI's competition here
Haemonetics Corporation (NYSE: HAE)
ICAD vs HAE Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while HAE trades at $102.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas HAE's P/E ratio is 20.54. In terms of profitability, ICAD's ROE is -0.18%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ICAD is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
ICAD vs LIVN Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while LIVN trades at $81.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas LIVN's P/E ratio is 19.46. In terms of profitability, ICAD's ROE is -0.18%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ICAD is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
ICAD vs ITGR Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while ITGR trades at $126.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ITGR's P/E ratio is 19.76. In terms of profitability, ICAD's ROE is -0.18%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ICAD is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ICAD vs IRTC Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while IRTC trades at $123.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas IRTC's P/E ratio is -287.05. In terms of profitability, ICAD's ROE is -0.18%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ICAD is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
ICAD vs AXNX Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ICAD's ROE is -0.18%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ICAD is similarly volatile compared to AXNX. This indicates similar risk in terms of short-term price fluctuations for ICAD.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ICAD vs TMDX Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while TMDX trades at $89.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas TMDX's P/E ratio is 45.68. In terms of profitability, ICAD's ROE is -0.18%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ICAD is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ICAD vs AXGN Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while AXGN trades at $48.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AXGN's P/E ratio is 127.05. In terms of profitability, ICAD's ROE is -0.18%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ICAD is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check AXGN's competition here
Neogen Corporation (NASDAQ: NEOG)
ICAD vs NEOG Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while NEOG trades at $11.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NEOG's P/E ratio is 42.25. In terms of profitability, ICAD's ROE is -0.18%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, ICAD is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ICAD vs UFPT Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while UFPT trades at $288.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas UFPT's P/E ratio is 29.50. In terms of profitability, ICAD's ROE is -0.18%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ICAD is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ICAD vs ESTA Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while ESTA trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ESTA's P/E ratio is -58.96. In terms of profitability, ICAD's ROE is -0.18%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ICAD is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
ICAD vs NVCR Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while NVCR trades at $17.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NVCR's P/E ratio is -13.80. In terms of profitability, ICAD's ROE is -0.18%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ICAD is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check NVCR's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ICAD vs NUVA Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ICAD's ROE is -0.18%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ICAD is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check NUVA's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ICAD vs BFLY Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BFLY has a market cap of 2B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while BFLY trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BFLY's P/E ratio is -30.67. In terms of profitability, ICAD's ROE is -0.18%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ICAD is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check BFLY's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ICAD vs INSP Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while INSP trades at $63.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas INSP's P/E ratio is 27.76. In terms of profitability, ICAD's ROE is -0.18%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ICAD is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
ICAD vs CNMD Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while CNMD trades at $49.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CNMD's P/E ratio is 10.84. In terms of profitability, ICAD's ROE is -0.18%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ICAD is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ICAD vs ATEC Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while ATEC trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ATEC's P/E ratio is -157.50. In terms of profitability, ICAD's ROE is -0.18%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ICAD is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check ATEC's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ICAD vs TNDM Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while TNDM trades at $19.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas TNDM's P/E ratio is -21.40. In terms of profitability, ICAD's ROE is -0.18%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ICAD is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check TNDM's competition here
Heska Corporation (NASDAQ: HSKA)
ICAD vs HSKA Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ICAD's ROE is -0.18%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ICAD is similarly volatile compared to HSKA. This indicates similar risk in terms of short-term price fluctuations for ICAD.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ICAD vs IART Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while IART trades at $16.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas IART's P/E ratio is 7.08. In terms of profitability, ICAD's ROE is -0.18%, compared to IART's ROE of -0.01%. Regarding short-term risk, ICAD is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ICAD vs PRCT Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while PRCT trades at $22.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PRCT's P/E ratio is -11.73. In terms of profitability, ICAD's ROE is -0.18%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ICAD is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check PRCT's competition here
Artivion, Inc. (NYSE: AORT)
ICAD vs AORT Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while AORT trades at $25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AORT's P/E ratio is 42.63. In terms of profitability, ICAD's ROE is -0.18%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ICAD is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check AORT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ICAD vs AVNS Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ICAD's ROE is -0.18%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ICAD is less volatile compared to AVNS. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ICAD vs LMRI Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while LMRI trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas LMRI's P/E ratio is -23.70. In terms of profitability, ICAD's ROE is -0.18%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ICAD is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ICAD vs SILK Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SILK's P/E ratio is -18.96. In terms of profitability, ICAD's ROE is -0.18%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ICAD is less volatile compared to SILK. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
ICAD vs IRMD Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while IRMD trades at $83.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas IRMD's P/E ratio is 43.51. In terms of profitability, ICAD's ROE is -0.18%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ICAD is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
ICAD vs FNA Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas FNA's P/E ratio is -19.83. In terms of profitability, ICAD's ROE is -0.18%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ICAD is less volatile compared to FNA. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
ICAD vs ENOV Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while ENOV trades at $18.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ENOV's P/E ratio is 5.31. In terms of profitability, ICAD's ROE is -0.18%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ICAD is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check ENOV's competition here
Bioventus Inc. (NASDAQ: BVS)
ICAD vs BVS Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BVS has a market cap of 953.2M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while BVS trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BVS's P/E ratio is 18.51. In terms of profitability, ICAD's ROE is -0.18%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ICAD is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ICAD vs CBLL Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CBLL has a market cap of 937.9M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while CBLL trades at $24.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CBLL's P/E ratio is -14.05. In terms of profitability, ICAD's ROE is -0.18%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, ICAD is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check CBLL's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ICAD vs AHCO Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AHCO has a market cap of 883M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while AHCO trades at $6.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AHCO's P/E ratio is 13.24. In terms of profitability, ICAD's ROE is -0.18%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ICAD is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ICAD vs AVR Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, AVR has a market cap of 879M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while AVR trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas AVR's P/E ratio is -4.66. In terms of profitability, ICAD's ROE is -0.18%, compared to AVR's ROE of -0.78%. Regarding short-term risk, ICAD is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check AVR's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ICAD vs BBNX Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BBNX has a market cap of 873.7M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while BBNX trades at $19.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BBNX's P/E ratio is -11.77. In terms of profitability, ICAD's ROE is -0.18%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ICAD is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check BBNX's competition here
InMode Ltd. (NASDAQ: INMD)
ICAD vs INMD Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, INMD has a market cap of 857M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while INMD trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas INMD's P/E ratio is 10.35. In terms of profitability, ICAD's ROE is -0.18%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ICAD is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ICAD vs CSII Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CSII's P/E ratio is -20.83. In terms of profitability, ICAD's ROE is -0.18%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ICAD is less volatile compared to CSII. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ICAD vs SIBN Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SIBN has a market cap of 820.5M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while SIBN trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SIBN's P/E ratio is -54.41. In terms of profitability, ICAD's ROE is -0.18%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ICAD is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check SIBN's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ICAD vs VREX Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, VREX has a market cap of 779.3M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while VREX trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas VREX's P/E ratio is 19.48. In terms of profitability, ICAD's ROE is -0.18%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ICAD is less volatile compared to VREX. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ICAD vs SSII Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SSII has a market cap of 682.4M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while SSII trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SSII's P/E ratio is -66.51. In terms of profitability, ICAD's ROE is -0.18%, compared to SSII's ROE of -0.27%. Regarding short-term risk, ICAD is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ICAD vs SRDX Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ICAD's ROE is -0.18%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ICAD is similarly volatile compared to SRDX. This indicates similar risk in terms of short-term price fluctuations for ICAD.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ICAD vs CTKB Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CTKB has a market cap of 607M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while CTKB trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CTKB's P/E ratio is -24.90. In terms of profitability, ICAD's ROE is -0.18%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ICAD is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check CTKB's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ICAD vs APEN Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas APEN's P/E ratio is -9.43. In terms of profitability, ICAD's ROE is -0.18%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ICAD is less volatile compared to APEN. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ICAD vs KIDS Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, KIDS has a market cap of 575.6M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while KIDS trades at $22.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas KIDS's P/E ratio is -18.99. In terms of profitability, ICAD's ROE is -0.18%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ICAD is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check KIDS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ICAD vs DCTH Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, DCTH has a market cap of 568.9M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while DCTH trades at $16.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas DCTH's P/E ratio is 1648.00. In terms of profitability, ICAD's ROE is -0.18%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ICAD is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ICAD vs ZIMV Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ICAD's ROE is -0.18%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ICAD is similarly volatile compared to ZIMV. This indicates similar risk in terms of short-term price fluctuations for ICAD.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
ICAD vs CERS Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CERS has a market cap of 521.9M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while CERS trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CERS's P/E ratio is -51.70. In terms of profitability, ICAD's ROE is -0.18%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ICAD is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ICAD vs NPCE Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NPCE has a market cap of 508M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while NPCE trades at $14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NPCE's P/E ratio is -26.14. In terms of profitability, ICAD's ROE is -0.18%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, ICAD is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check NPCE's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ICAD vs TCMD Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, TCMD has a market cap of 493.3M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while TCMD trades at $21.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas TCMD's P/E ratio is 20.25. In terms of profitability, ICAD's ROE is -0.18%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, ICAD is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ICAD vs SGHT Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SGHT has a market cap of 454.3M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while SGHT trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SGHT's P/E ratio is -14.91. In terms of profitability, ICAD's ROE is -0.18%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ICAD is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
ICAD vs CARL Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CARL has a market cap of 424.1M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while CARL trades at $15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CARL's P/E ratio is -10.91. In terms of profitability, ICAD's ROE is -0.18%, compared to CARL's ROE of -0.38%. Regarding short-term risk, ICAD is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ICAD vs PACB Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PACB has a market cap of 419.3M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while PACB trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PACB's P/E ratio is -3.29. In terms of profitability, ICAD's ROE is -0.18%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ICAD is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check PACB's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ICAD vs CLPT Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CLPT has a market cap of 418.7M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while CLPT trades at $13.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CLPT's P/E ratio is -11.83. In terms of profitability, ICAD's ROE is -0.18%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ICAD is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ICAD vs SENS Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SENS has a market cap of 402.5M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while SENS trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SENS's P/E ratio is -4.32. In terms of profitability, ICAD's ROE is -0.18%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ICAD is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ICAD vs OFIX Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, OFIX has a market cap of 375.5M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while OFIX trades at $9.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas OFIX's P/E ratio is -6.05. In terms of profitability, ICAD's ROE is -0.18%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ICAD is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check OFIX's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ICAD vs CATX Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CATX has a market cap of 358.1M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while CATX trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CATX's P/E ratio is -2.36. In terms of profitability, ICAD's ROE is -0.18%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ICAD is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check CATX's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ICAD vs TMCI Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, TMCI has a market cap of 312M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while TMCI trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas TMCI's P/E ratio is -5.12. In terms of profitability, ICAD's ROE is -0.18%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ICAD is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check TMCI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ICAD vs SMLR Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ICAD's ROE is -0.18%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ICAD is similarly volatile compared to SMLR. This indicates similar risk in terms of short-term price fluctuations for ICAD.Check SMLR's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ICAD vs TLSI Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, TLSI has a market cap of 307.9M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while TLSI trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas TLSI's P/E ratio is -2.98. In terms of profitability, ICAD's ROE is -0.18%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ICAD is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
ICAD vs CV Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, CV has a market cap of 299.3M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while CV trades at $5.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas CV's P/E ratio is -2.40. In terms of profitability, ICAD's ROE is -0.18%, compared to CV's ROE of -1.78%. Regarding short-term risk, ICAD is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check CV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ICAD vs RCEL Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, RCEL has a market cap of 278.2M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while RCEL trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas RCEL's P/E ratio is -7.78. In terms of profitability, ICAD's ROE is -0.18%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ICAD is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check RCEL's competition here
RxSight, Inc. (NASDAQ: RXST)
ICAD vs RXST Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, RXST has a market cap of 263.9M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while RXST trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas RXST's P/E ratio is -5.64. In terms of profitability, ICAD's ROE is -0.18%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ICAD is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check RXST's competition here
Profound Medical Corp. (NASDAQ: PROF)
ICAD vs PROF Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, PROF has a market cap of 250.4M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while PROF trades at $6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas PROF's P/E ratio is -7.03. In terms of profitability, ICAD's ROE is -0.18%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ICAD is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check PROF's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
ICAD vs INFU Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, INFU has a market cap of 246M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while INFU trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas INFU's P/E ratio is 29.73. In terms of profitability, ICAD's ROE is -0.18%, compared to INFU's ROE of +0.15%. Regarding short-term risk, ICAD is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ICAD vs MGRM Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ICAD's ROE is -0.18%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ICAD is similarly volatile compared to MGRM. This indicates similar risk in terms of short-term price fluctuations for ICAD.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
ICAD vs ELMD Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, ELMD has a market cap of 232.1M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while ELMD trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas ELMD's P/E ratio is 21.40. In terms of profitability, ICAD's ROE is -0.18%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, ICAD is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
ICAD vs NVRO Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ICAD's ROE is -0.18%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ICAD is less volatile compared to NVRO. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ICAD vs STIM Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, STIM has a market cap of 200.4M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while STIM trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas STIM's P/E ratio is -6.55. In terms of profitability, ICAD's ROE is -0.18%, compared to STIM's ROE of -1.51%. Regarding short-term risk, ICAD is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ICAD vs BSGM Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ICAD's ROE is -0.18%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ICAD is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
ICAD vs LUCD Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, LUCD has a market cap of 179.2M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while LUCD trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas LUCD's P/E ratio is -2.54. In terms of profitability, ICAD's ROE is -0.18%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, ICAD is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ICAD vs MDGS Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ICAD's ROE is -0.18%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ICAD is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ICAD vs QIPT Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ICAD's ROE is -0.18%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ICAD is similarly volatile compared to QIPT. This indicates similar risk in terms of short-term price fluctuations for ICAD.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ICAD vs FOCL Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, FOCL has a market cap of 155.6M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while FOCL trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas FOCL's P/E ratio is -4.01. In terms of profitability, ICAD's ROE is -0.18%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, ICAD is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check FOCL's competition here
Quantum-Si incorporated (NASDAQ: QSI)
ICAD vs QSI Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, QSI has a market cap of 151.5M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while QSI trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas QSI's P/E ratio is -1.67. In terms of profitability, ICAD's ROE is -0.18%, compared to QSI's ROE of -0.47%. Regarding short-term risk, ICAD is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check QSI's competition here
Inogen, Inc. (NASDAQ: INGN)
ICAD vs INGN Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, INGN has a market cap of 146.7M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while INGN trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas INGN's P/E ratio is -5.96. In terms of profitability, ICAD's ROE is -0.18%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ICAD is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
ICAD vs QTRX Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, QTRX has a market cap of 126.7M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while QTRX trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas QTRX's P/E ratio is -1.06. In terms of profitability, ICAD's ROE is -0.18%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ICAD is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check QTRX's competition here
LENSAR Inc (NASDAQ: LNSR)
ICAD vs LNSR Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, LNSR has a market cap of 105.4M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while LNSR trades at $8.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas LNSR's P/E ratio is 8.76. In terms of profitability, ICAD's ROE is -0.18%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, ICAD is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check LNSR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ICAD vs HJLI Comparison September 2026
iCAD, Inc. (NASDAQ: ICAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICAD stands at 106.3M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ICAD is priced at $3.87 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICAD currently has a P/E ratio of -20.37, whereas HJLI's P/E ratio is N/A. In terms of profitability, ICAD's ROE is -0.18%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ICAD is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for ICAD.Check HJLI's competition here